Thus, the recurrent and dominant negative nature of RHOA mutations in AITL, PTCL, BL and DLBCL strongly support a tumor suppressive role for RHOA in hematological cancers. This evidence concerns the gene RHOA and diffuse large B-cell lymphoma.